Medi-Span vs RxLabelGuard: Which Drug Interaction API Fits Your Stack?

Medi-Span is the industry standard for pharmacy drug data. Maintained by Wolters Kluwer, it powers a significant share of the pharmacy dispensing, PBM adjudication, and clinical decision support systems in the United States. If you have filled a prescription at a major pharmacy chain, there is a good chance Medi-Span data was involved somewhere in the pipeline.

But Medi-Span is a broad drug data platform. It covers drug pricing, NDC directory management, Generic Product Identifier classification, allergy cross-referencing, duplicate therapy detection, and dose range checking, in addition to drug-drug interaction screening. Many development teams building focused drug interaction features only need one slice of what Medi-Span offers, and paying for the full suite may not match their requirements or budget.

RxLabelGuard takes a narrower approach: a REST API built specifically for drug-drug interaction checking, sourced from FDA Structured Product Labeling via openFDA, with AI-powered extraction and severity scoring. This post compares the two approaches across five dimensions that matter most to developers evaluating their options. For a broader side-by-side feature breakdown, see the full comparison at /alternatives/medi-span.

Medi-Span's interaction data comes from a proprietary editorial database maintained by Wolters Kluwer's team of clinical pharmacists. This team reviews primary literature, FDA labeling changes, and post-market surveillance data to curate interaction monographs. Each monograph includes a detailed clinical description, severity classification, documentation quality rating, and management recommendations. The editorial process produces high-quality, clinically validated content, and it covers drug-drug, drug-allergy, drug-food, duplicate therapy, and drug-disease interactions.

RxLabelGuard's interaction data is derived from a different source: FDA Structured Product Labeling. Every FDA-approved drug has an SPL document that includes a drug interactions section written or approved by the manufacturer and reviewed by the FDA. RxLabelGuard retrieves these labels through the openFDA API, then uses a two-pass extraction pipeline, first deterministic keyword matching, then AI structuring via AWS Bedrock, to produce structured interaction records with severity levels and evidence citations.

These are fundamentally different data lineages. Medi-Span offers editorially curated breadth across multiple interaction categories. RxLabelGuard offers FDA-sourced depth specifically for drug-drug interactions, with every result traceable to a specific label section and SPL Set ID. The right choice depends on whether you need the full clinical data suite or focused drug-drug interaction checking with transparent evidence chains. The /alternatives/medi-span page breaks down the coverage differences in more detail.

Medi-Span historically operates on a data feed model. Customers receive periodic data file deliveries, typically weekly, which they load into their own database infrastructure. The consuming application queries a local copy of the Medi-Span dataset rather than calling a remote API endpoint. This model gives complete control over query performance and availability, but it requires database infrastructure, an ETL pipeline to ingest updates, and operational maintenance for the local data store.

More recently, Wolters Kluwer has released the Medi-Span Expert AI MCP server, which enables AI assistants and large language model applications to access Medi-Span data through the Model Context Protocol. This is a significant step toward more modern integration patterns, though it targets AI assistant workflows rather than traditional REST API consumption by application backends.

RxLabelGuard provides a conventional REST API with JSON request and response payloads. You provision an API key through the self-service dashboard, make POST requests to the /v1/interactions/check endpoint, and receive structured JSON responses with interaction pairs, severity levels, mechanisms, recommendations, and evidence citations. The full endpoint specification is documented at /docs/check-interactions, and the API reference is available at /docs. There is no data feed to manage, no local database to maintain, and no ETL pipeline to build.

For teams building traditional web applications, mobile backends, or microservice architectures, the REST API model means you can go from signup to a working integration in an afternoon. For teams building enterprise pharmacy or PBM systems that already manage complex data infrastructure, the Medi-Span feed model may align better with existing operational patterns.

This is where the two products diverge most sharply. Medi-Span uses enterprise licensing with no publicly listed pricing. You contact the Wolters Kluwer sales team, negotiate terms based on your use case and volume, and sign an annual contract. This is standard for enterprise healthcare data products, but it means you cannot evaluate cost until you have engaged the sales process, and minimum commitments may be substantial.

RxLabelGuard publishes its pricing at /pricing with a straightforward tier structure. The pricing model is designed for self-service adoption with no sales engagement required.

Medi-Span uses a two-axis classification system for drug interactions: clinical significance and documentation quality. The clinical significance axis rates the potential severity of the interaction outcome, while the documentation axis rates the strength of the evidence supporting the interaction. This produces a matrix that helps clinicians and CDS systems distinguish between well-documented serious interactions and poorly documented theoretical ones. Each interaction includes a detailed monograph with mechanism, clinical effects, and management recommendations written by clinical pharmacists.

RxLabelGuard assigns one of five severity levels to each interaction: contraindicated, major, moderate, minor, or unknown. These levels are derived from the language used in the source FDA label, assigned through a combination of deterministic keyword analysis and AI-powered text classification. Each interaction result includes the evidence snippet, the specific excerpt from the FDA label that informed the severity assignment, along with the SPL Set ID for direct traceability to the source document. For a detailed explanation of how these severity tiers work in practice, see /blog/drug-interaction-severity-levels-explained.

Medi-Span has deeper clinical editorial content and the two-axis scoring system provides more granular classification. RxLabelGuard has transparent FDA-sourced evidence chains where every severity assignment links directly to the regulatory label text. If your application needs to show clinicians or auditors exactly where an interaction finding came from, the FDA citation model is valuable. If your application needs the richest possible clinical narrative for each interaction, Medi-Span's editorial monographs are hard to match.

Medi-Span is the stronger fit when your project requires the full breadth of drug data services beyond just interactions. If you are building a pharmacy dispensing system, a PBM adjudication engine, or a comprehensive clinical decision support platform that needs drug pricing, allergy checking, duplicate therapy detection, and dose range validation alongside interaction screening, Medi-Span delivers all of that in a single licensed dataset. It is also the established choice for organizations that already operate data feed infrastructure and prefer to query a local database rather than depend on an external API.

RxLabelGuard is the stronger fit when your specific need is drug-drug interaction checking via a REST API. If you are building a medication safety feature into an existing EHR integration, developing a clinical tool that needs audit-ready FDA evidence citations, prototyping an MVP with transparent pricing, or adding interaction checking to a telehealth or e-prescribing workflow, the self-service model gets you to production faster. You can sign up at /register, provision an API key, and start making requests in minutes rather than weeks.

For teams evaluating multiple options beyond these two, the /compare page provides broader context across the clinical decision support landscape, including comparisons with First Databank, Clinical Pharmacology, and other alternatives.

If you want to evaluate RxLabelGuard against your requirements, the free tier provides full API access with 100 requests per day at no cost and no sales call. Sign up at /register, review the API documentation at /docs, and check the published pricing at /pricing to understand the upgrade path if your usage grows.

For the complete feature-by-feature comparison with Medi-Span, including data update frequency, supported identifiers, and compliance considerations, see the full analysis at /alternatives/medi-span. All interaction data returned by RxLabelGuard is derived from FDA Structured Product Labeling and is provided for informational purposes. It should not be used as a substitute for professional medical advice, diagnosis, or treatment.